Print this page    •   Back to Web version of article

Medical News
Two- to Sixfold Decreased Odds of HIV Risk Behavior Associated With Use of Syringe Exchange

November 7, 2002

This community study of the San Jose, Calif. syringe exchange program (SEP) compared the HIV risk behavior of exchange clients with that of nonclients. The researchers followed a prospective cohort of 259 untreated injection drug users a mean of 10.7 months after baseline. The current study corrected for respondents' baseline risk behavior in analyzing the association between the patients' follow-up use of the syringe exchange program and their follow-up risk behavior. The authors also attempted to adjust for other sources of syringes by measuring and analyzing respondents' use of sterile syringes from non-SEP sources. Analysis of potential confounders showed that the variables sex, number of injections in the previous 30 days, and number of "speedball" (heroin and cocaine) injections were significantly associated with risk behavior at follow-up.

Seventy-seven percent of the sample of predominantly male, Hispanic patients in their thirties and forties was reached for follow-up interviews. Data analysis showed a greater than twofold protective effect associated with use of syringe exchange, although the authors stress that such an association could be due in part to preexisting differences between IDUs who seek and those who do not seek to use an SEP. Analysis examining the interaction of exchange use with other sources of syringes showed the odds of HIV risk behavior were decreased more than sixfold for IDUs who obtained syringes only from the SEP.

The findings of this study support the bulk of the literature evaluating syringe exchange: the protective effect associated with such programs is considerable. Furthermore, the finding that the protective effect increases sixfold against HIV risk for IDUs without other sources of syringes emphasizes the critical nature of such programs and suggests that syringe exchange programs can gain great benefit from focusing on getting sterile syringes to these IDUs.

Back to other CDC news for November 7, 2002

Previous Updates

Excerpted from:
Journal of Acquired Immune Deficiency Syndromes
10.01.02; Vol. 31: P. 237-242; David R. Gibson; Richard Brand; Kim Anderson; James G. Kahn; Daniel Perales; Joseph Guydish

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.